Revenue
$141.01M
Fiscal year ended 2026-06-30Operating income
$34.94M
Fiscal year ended 2026-06-30Free cash flow
$17.53M
Fiscal year ended 2026-06-30ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported revenue of $141.01M and net income of $56.67M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ELITE PHARMACEUTICALS INC /NV/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $141.01M |
| Cost of revenue | $79.71M |
| Gross profit | $61.31M |
| Operating income | $34.94M |
| Net income | $56.67M |
| Research & development | $6.10M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $65.10M |
| Income tax expense | $8.43M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | Unavailable |
| General & administrative | $17.74M |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $139.67M |
| Current assets | $114.49M |
| Total liabilities | $34.84M |
| Current liabilities | $30.44M |
| Total equity incl. NCI | $104.83M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $24.20M |
| Accounts receivable | $50.44M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $5.59M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $19.04M |
| Capital expenditures | $1.52M |
| Investing cash flow | -$1.52M |
| Financing cash flow | -$306.22K |
| Net change in cash | $17.22M |
| Stock-based compensation | Unavailable |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $1.17M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $17.53M |
| Gross margin | 43.5% |
| Operating margin | 24.8% |
| FCF margin | 12.4% |
| SBC / revenue | Unavailable |
| Current ratio | 3.76x |
| Revenue YoY growth | 33.7% |
| Net margin | 40.2% |
| R&D / revenue | 4.3% |
| CapEx / revenue | 1.1% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | 12.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELTP in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-29View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-K · Filed 2025-06-30View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.